Chatham Capital Group Inc. Has $6.49 Million Stake in AbbVie Inc. $ABBV

Chatham Capital Group Inc. lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 8.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,011 shares of the company’s stock after selling 2,440 shares during the quarter. AbbVie comprises 0.9% of Chatham Capital Group Inc.’s investment portfolio, making the stock its 27th biggest holding. Chatham Capital Group Inc.’s holdings in AbbVie were worth $6,486,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Brighton Jones LLC boosted its position in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares in the last quarter. Warwick Investment Management Inc. raised its holdings in shares of AbbVie by 20.5% in the first quarter. Warwick Investment Management Inc. now owns 2,319 shares of the company’s stock valued at $486,000 after purchasing an additional 395 shares during the last quarter. Ieq Capital LLC increased its stake in AbbVie by 49.8% in the 1st quarter. Ieq Capital LLC now owns 114,761 shares of the company’s stock valued at $24,045,000 after buying an additional 38,156 shares during the last quarter. Finally, CreativeOne Wealth LLC increased its position in shares of AbbVie by 4.2% during the first quarter. CreativeOne Wealth LLC now owns 42,217 shares of the company’s stock valued at $8,845,000 after acquiring an additional 1,712 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Wells Fargo & Company increased their price objective on AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Citigroup reduced their price target on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. Guggenheim boosted their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a research note on Thursday, October 9th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Stock Up 0.6%

NYSE ABBV opened at $230.18 on Thursday. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.72 and a quick ratio of 0.60. The stock has a market capitalization of $406.81 billion, a PE ratio of 174.38, a PEG ratio of 1.30 and a beta of 0.36. The business’s 50-day moving average is $226.65 and its 200 day moving average is $212.00. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period in the prior year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 496.97%.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.